Compare Recursion Pharmaceuticals Inc (RXRX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Wix.Com Ltd — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Wix.Com Ltd trades at $73.87 (market cap $3.04B). The key difference: Wix.Com Ltd is the larger of the two by market cap, and Wix.Com Ltd is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | WIX | |
|---|---|---|
Market Cap | $1.86B | $3.04B |
Sector | Health | Technology |
52-Week High | $6.79 | $184.24 |
52-Week Low | $2.84 | $40.43 |
Enterprise Value | $1.38B | $4.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
WIX trades at $72.72, down 4.58% in the last session, with a bearish technical signal and negative net cash flow of -$344.06M in 2025. Revenue grew to $1.99B in 2025, but net income margin remains negative at -8.19% for 2026. The stock faces multiple class action lawsuits alleging securities fraud, with a deadline of September 22, 2026, adding legal overhangs.
The outlook is mixed: analyst consensus is a Buy with a $73.36 target, near the current price, but risks from litigation and volatile earnings pose headwinds. Investment opportunity hinges on execution amid competitive pressures, while downside protection is limited by weak profitability and negative shareholder equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
